Logo image of ANIK

ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK - US0352551081 - Common Stock

9.33 USD
+0.1 (+1.08%)
Last: 8/29/2025, 9:42:05 AM
Fundamental Rating

4

Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ANIK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ANIK has reported negative net income.
In the past year ANIK had a positive cash flow from operations.
In the past 5 years ANIK reported 4 times negative net income.
ANIK had a positive operating cash flow in 4 of the past 5 years.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

ANIK's Return On Assets of -32.30% is fine compared to the rest of the industry. ANIK outperforms 64.72% of its industry peers.
With a decent Return On Equity value of -41.05%, ANIK is doing good in the industry, outperforming 71.12% of the companies in the same industry.
Industry RankSector Rank
ROA -32.3%
ROE -41.05%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

ANIK has a Gross Margin of 56.82%. This is in the better half of the industry: ANIK outperforms 77.15% of its industry peers.
In the last couple of years the Gross Margin of ANIK has declined.
ANIK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANIK has less shares outstanding than it did 1 year ago.
ANIK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ANIK has an Altman-Z score of 3.46. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
ANIK has a better Altman-Z score (3.46) than 74.77% of its industry peers.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.46
ROIC/WACCN/A
WACC9.7%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 6.18 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a better Current ratio (6.18) than 63.99% of its industry peers.
A Quick Ratio of 5.12 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a Quick ratio (5.12) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 6.18
Quick Ratio 5.12
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.25% over the past year.
ANIK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.85%.
Measured over the past years, ANIK shows a small growth in Revenue. The Revenue has been growing by 0.91% on average per year.
EPS 1Y (TTM)53.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2700%
Revenue 1Y (TTM)-25.85%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-32.69%

3.2 Future

Based on estimates for the next years, ANIK will show a very strong growth in Earnings Per Share. The EPS will grow by 28.24% on average per year.
ANIK is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.88% yearly.
EPS Next Y43.83%
EPS Next 2Y34.7%
EPS Next 3Y25.78%
EPS Next 5Y28.24%
Revenue Next Year-26.1%
Revenue Next 2Y-11.77%
Revenue Next 3Y-5.52%
Revenue Next 5Y11.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

ANIK's earnings are expected to grow with 25.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.7%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (8/29/2025, 9:42:05 AM)

9.33

+0.1 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-29 2025-10-29/amc
Inst Owners90.54%
Inst Owner Change-0.08%
Ins Owners4.23%
Ins Owner Change17.1%
Market Cap134.54M
Analysts86.67
Price Target18.7 (100.43%)
Short Float %2.67%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.46%
Min EPS beat(2)-132.56%
Max EPS beat(2)-8.36%
EPS beat(4)0
Avg EPS beat(4)-518.35%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-8.36%
EPS beat(8)0
Avg EPS beat(8)-472.04%
EPS beat(12)2
Avg EPS beat(12)-316.38%
EPS beat(16)5
Avg EPS beat(16)-229.59%
Revenue beat(2)1
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-8.59%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)-0.68%
Revenue beat(12)8
Avg Revenue beat(12)0.79%
Revenue beat(16)12
Avg Revenue beat(16)2.36%
PT rev (1m)-14.06%
PT rev (3m)-20.29%
EPS NQ rev (1m)-46.42%
EPS NQ rev (3m)-396.96%
EPS NY rev (1m)-3.64%
EPS NY rev (3m)-35.71%
Revenue NQ rev (1m)0.36%
Revenue NQ rev (3m)-1.23%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.09
P/FCF N/A
P/OCF 21.43
P/B 0.91
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.44
OCFY4.67%
SpS8.58
BVpS10.24
TBVpS9.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.3%
ROE -41.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.82%
FCFM N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.79%
Cap/Sales 5.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.18
Quick Ratio 5.12
Altman-Z 3.46
F-Score6
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2700%
EPS Next Y43.83%
EPS Next 2Y34.7%
EPS Next 3Y25.78%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-25.85%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-32.69%
Revenue Next Year-26.1%
Revenue Next 2Y-11.77%
Revenue Next 3Y-5.52%
Revenue Next 5Y11.88%
EBIT growth 1Y9.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.18%
EBIT Next 3Y32.7%
EBIT Next 5Y36.1%
FCF growth 1Y92.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.01%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%